Xpert® MTB/XDR

Home / Tests / TB & Emerging Infectious Diseases

Xpert® MTB/XDR

Simplifying TB drug susceptibility testing utilizing increased multiplexing capability with 10 color GeneXpert® technology

Test pack size(s)

10 Tests

GXMTB/XDR-10

Qty

Unit price

Subtotal

USD

$0.00

Total

$0.00

The Need

In 2022, only 43% of the total estimated multidrug-resistant Tuberculosis (MDR-TB) incident cases were diagnosed and enrolled on treatment regimen¹
Only 47% of the total notified MDR-TB cases were tested for resistance to fluoroquinolones¹
Increase access to rapid and extended drug resistance profiling for all TB-positive cases to rule out MDR/pre-XDR^{^} TB2

1 World Health Organization Tuberculosis Report 2023--https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023/tb-disease-burden/1-3-drug-resistant-tb. Accessed January 2024.
2 Global Plan to End TB, STOP TB Report- https://omnibook.com/api/export/1.0/dc664b3a-14b4-4cc0-8042-ea8f27e902a6/-1/0/pdf^ Pre-XDR: Pre-Extensive Drug Resistant TB
^ Pre-XDR: Pre-Extensive Drug Resistant TB

The Solution

The Xpert MTB/XDR test enables rapid molecular DST. When combined with the frontline Xpert MTB/RIF Ultra test, it sets new standards by detecting mutations associated with resistance to isoniazid (INH), fluoroquinolones (FLQ), second-line injectable drugs (SLIDs), and ethionamide (ETH) in a single test.

Fast time to result for molecular DST
Results in <90 minutes
Same easy-to-use process as the Xpert MTB/RIF Ultra test
Run on existing GeneXpert® platforms equipped with 10-color modules

The Impact

Upfront molecular DST for all TB-positive cases enables optimized treatment in a single visit
Increased access to drug-resistance testing with Xpert MTB/XDR help notify more people affected with MDR and Pre-XDR TB³
The Xpert MTB/XDR assay provides the capability to differentiate between high and low-level resistance to INH and FLQ, which is important for determining therapeutic options and individualized treatment regimens⁴

3 Adam Penn-Nicholson et al. 2022 https://www.medrxiv.org/content/10.1101/2021.05.06.21256505v1.full.pdf
4 L Saderi, et al. 2022 https://www.archbronconeumol.org/es-pdf-S0300289622004987